Atria Investments LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 27.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,137 shares of the biopharmaceutical company’s stock after purchasing an additional 3,285 shares during the quarter. Atria Investments LLC’s holdings in Gilead Sciences were worth $1,071,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Bank of New York Mellon Corp grew its stake in shares of Gilead Sciences by 9.8% in the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock worth $2,076,368,000 after purchasing an additional 2,727,063 shares during the last quarter. Parnassus Investments CA grew its stake in shares of Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after purchasing an additional 4,556,901 shares during the last quarter. APG Asset Management N.V. grew its stake in shares of Gilead Sciences by 16.7% in the first quarter. APG Asset Management N.V. now owns 5,923,426 shares of the biopharmaceutical company’s stock worth $402,319,000 after purchasing an additional 849,741 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Gilead Sciences by 25.7% in the first quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock worth $354,070,000 after purchasing an additional 1,066,172 shares during the last quarter. Finally, Swiss National Bank grew its stake in shares of Gilead Sciences by 26.9% in the first quarter. Swiss National Bank now owns 4,668,124 shares of the biopharmaceutical company’s stock worth $317,059,000 after purchasing an additional 989,400 shares during the last quarter. 73.97% of the stock is currently owned by institutional investors.

Shares of Gilead Sciences, Inc. (GILD) traded up 0.32% during midday trading on Wednesday, reaching $82.55. 2,664,986 shares of the company’s stock were exchanged. The stock’s 50-day moving average is $77.54 and its 200 day moving average is $70.38. The firm has a market cap of $107.80 billion, a PE ratio of 8.97 and a beta of 1.19. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business’s quarterly revenue was down 8.2% on a year-over-year basis. During the same quarter last year, the company posted $3.08 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post $8.78 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.53%. Gilead Sciences’s dividend payout ratio is currently 22.58%.

ILLEGAL ACTIVITY NOTICE: This piece was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/20/gilead-sciences-inc-gild-position-increased-by-atria-investments-llc.html.

Several research firms recently issued reports on GILD. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Argus raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price on the stock in a research note on Thursday, August 31st. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 target price on the stock. in a research note on Monday, August 28th. Cowen and Company reissued an “outperform” rating and issued a $90.00 target price on shares of Gilead Sciences in a research note on Wednesday, July 5th. Finally, Wells Fargo & Company raised their target price on Gilead Sciences from $73.00 to $81.00 and gave the stock a “market perform” rating in a research note on Wednesday, September 6th. Eleven equities research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $83.79.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the transaction, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The disclosure for this sale can be found here. In the last ninety days, insiders sold 466,819 shares of company stock valued at $36,740,240. Corporate insiders own 1.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.